Karyopharm Therapeutics Company Profile (NASDAQ:KPTI)

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. Its product pipeline includes Verdinexor (KPT-335), an oral SINE compound; KPT-9274, a dual p21-activated kinase 4 (PAK4)/Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, and KPT-350, a compound in development for the treatment of neurological disorders.

Industry, Sector and Symbol:

Sector: Medical
Industry: Drugs - Generic
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: KPTI
CUSIP:

Key Metrics:

Previous Close: $9.35
50 Day Moving Average: $8.33
200 Day Moving Average: $8.28
52-Week Range: $35,989,000.00 - $4.83
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -3.00
P/E Growth: 0.21
Market Cap: $336.50M
Outstanding Shares: 35,989,000
Beta: 4.25

Profitability:

Return on Equity: -62.24%
Return on Assets: -57.21%

Debt:

Current Ratio: 8.00%
Quick Ratio: 8.00%

Additional Links:

Companies Related to Karyopharm Therapeutics:

Consensus Ratings for Karyopharm Therapeutics (NASDAQ:KPTI) (?)

Ratings Breakdown:	1 Sell Rating, 10 Buy Ratings
Consensus Rating:	Buy (Score: 2.82)
Consensus Price Target:	$16.21 (73.40% upside)

Analysts' Ratings History for Karyopharm Therapeutics (NASDAQ:KPTI)

Show:

Date	Firm	Action	Rating	Price Target
9/8/2016	Jefferies Group	Reiterated Rating	Buy	$12.00
9/8/2016	HC Wainwright	Boost Price Target	Buy	$15.00 -> $16.00
9/6/2016	Robert W. Baird	Reiterated Rating	Positive	$16.00
8/30/2016	S&P Equity Research	Lower Price Target		$9.06 -> $7.55
8/6/2016	Canaccord Genuity	Set Price Target	Buy	$20.00
8/4/2016	Wedbush	Reiterated Rating	Outperform	$14.00
6/27/2016	Leerink Swann	Reiterated Rating	Buy
5/27/2016	Raymond James Financial Inc.	Initiated Coverage	Outperform	$13.00
3/15/2016	Bank of America Corp.	Downgrade	Neutral -> Underperform	$26.00 -> $11.00
3/14/2016	JPMorgan Chase & Co.	Lower Price Target	Overweight	$20.00 -> $19.00
3/9/2016	JMP Securities	Lower Price Target	Market Outperform	$58.00 -> $28.00
12/22/2015	FBR & Co	Reiterated Rating	Buy	$20.00
8/12/2015	MLV & Co.	Lower Price Target	Buy	$54.00 -> $42.00
3/17/2015	Oppenheimer Holdings Inc.	Reiterated Rating	Outperform	$53.00
11/5/2014	Barrington Research	Initiated Coverage	Buy	$54.00

(Data available from 9/26/2014 forward)

Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)

Date	Quarter	Consensus Estimate	Actual EPS	Release Link	Conference Call
11/7/2016
8/4/2016	Q216	($0.76)	($0.84)	View	N/A
5/9/2016	Q116	($0.74)	($0.75)	View	N/A
3/14/2016	Q415	($0.82)	($0.81)	View	Listen
11/9/2015	Q315	($0.87)	($0.85)	View	Listen
8/10/2015	Q215	($0.77)	($0.92)	View	Listen
5/11/2015	Q115	($0.75)	($0.74)	View	Listen
3/16/2015	Q414	($0.66)	($0.79)	View	Listen
11/10/2014	Q314	($0.52)	($0.61)	View	N/A
8/7/2014	Q214	($0.50)	($1.02)	View	N/A
5/7/2014		($0.47)	($0.46)	View	N/A
3/5/2014		($0.34)	($2.00)	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)

Current Year EPS Consensus Estimate: $-3.22 EPS
Next Year EPS Consensus Estimate: $-3.12 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	4	($0.79)	($0.73)	($0.75)
Q2 2016	3	($0.76)	($0.73)	($0.74)
Q3 2016	3	($0.83)	($0.75)	($0.79)
Q4 2016	3	($0.84)	($0.76)	($0.80)
Q1 2017	1	($0.62)	($0.62)	($0.62)
Q2 2017	1	($0.60)	($0.60)	($0.60)
Q3 2017	1	($0.62)	($0.62)	($0.62)
Q4 2017	1	($0.64)	($0.64)	($0.64)

(Data provided by Zacks Investment Research)

Dividend History for Karyopharm Therapeutics (NASDAQ:KPTI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Karyopharm Therapeutics (NASDAQ:KPTI)

Insider Ownership Percentage: 14.79%
Institutional Ownership Percentage: 55.71%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
6/23/2016	Ltd Chione	Major Shareholder	Sell	18,824	$8.03	$151,156.72
6/13/2016	Ltd Chione	Major Shareholder	Sell	7,074	$8.51	$60,199.74
6/9/2016	Ltd Chione	Major Shareholder	Sell	45,541	$9.21	$419,432.61
6/7/2016	Ltd Chione	Major Shareholder	Sell	40,000	$9.24	$369,600.00
6/2/2016	Ltd Chione	Major Shareholder	Sell	17,855	$9.65	$172,300.75
6/1/2016	Ltd Chione	Major Shareholder	Sell	74,664	$9.61	$717,521.04
5/31/2016	Ltd Chione	Major Shareholder	Sell	17,096	$9.66	$165,147.36
5/27/2016	Ltd Chione	Major Shareholder	Sell	40,000	$9.58	$383,200.00
5/26/2016	Ltd Chione	Major Shareholder	Sell	46,122	$9.73	$448,767.06
5/23/2016	Ltd Chione	Major Shareholder	Sell	93,932	$8.54	$802,179.28
5/18/2016	Ltd Chione	Major Shareholder	Sell	63,800	$8.15	$519,970.00
5/16/2016	Ltd Chione	Major Shareholder	Sell	10,400	$8.01	$83,304.00
5/11/2016	Ltd Chione	Major Shareholder	Sell	31,868	$8.24	$262,592.32
12/8/2015	Mansoor Raza Mirza	Director	Sell	15,000	$15.01	$225,150.00
4/7/2015	Ran Frenkel	EVP	Buy	3,000	$31.81	$95,430.00
4/2/2015	Barry E Greene	Director	Buy	3,000	$29.31	$87,930.00
4/2/2015	Justin A Renz	CFO	Buy	5,000	$29.71	$148,550.00
1/12/2015	Deepika Pakianathan	Director	Buy	45,454	$33.00	$1,499,982.00
1/12/2015	Michael Kauffman	CEO	Sell	50,000	$33.00	$1,650,000.00
1/12/2015	Sharon Shacham	Insider	Sell	25,000	$33.00	$825,000.00
12/2/2014	Mansoor Raza Mirza	Director	Sell	10,000	$43.52	$435,200.00
12/1/2014	Ltd Chione	Major Shareholder	Sell	278,115	$41.92	$11,658,580.80
11/25/2014	Ltd Chione	Major Shareholder	Sell	242,800	$42.40	$10,294,720.00
11/19/2014	Ltd Chione	Major Shareholder	Sell	65,968	$40.09	$2,644,657.12
11/12/2014	Ltd Chione	Major Shareholder	Sell	164,100	$42.83	$7,028,403.00
11/11/2014	Ltd Chione	Major Shareholder	Sell	54,100	$42.51	$2,299,791.00
11/10/2014	Ltd Chione	Major Shareholder	Sell	65,000	$43.40	$2,821,000.00
11/10/2014	Mansoor Raza Mirza	Director	Sell	5,000	$45.05	$225,250.00
11/6/2014	Ltd Chione	Major Shareholder	Sell	272,784	$42.11	$11,486,934.24
10/29/2014	Mansoor Raza Mirza	Director	Sell	3,500	$40.05	$140,175.00
9/26/2014	Marcin Czernik	Major Shareholder	Sell	50,000	$42.54	$2,127,000.00
9/24/2014	Marcin Czernik	Major Shareholder	Sell	22,498	$40.32	$907,119.36
9/18/2014	Marcin Czernik	Major Shareholder	Sell	12,347	$40.24	$496,843.28
9/17/2014	Marcin Czernik	Major Shareholder	Sell	9,569	$40.26	$385,247.94
9/12/2014	Ltd Chione	Major Shareholder	Sell	4,312	$41.12	$177,309.44
9/8/2014	Marcin Czernik	Major Shareholder	Sell	35,666	$39.92	$1,423,786.72
9/4/2014	Marcin Czernik	Major Shareholder	Sell	12,795	$38.07	$487,105.65
8/27/2014	Marcin Czernik	Major Shareholder	Sell	43,699	$38.80	$1,695,521.20
8/25/2014	Marcin Czernik	Major Shareholder	Sell	4,389	$38.08	$167,133.12
8/15/2014	Marcin Czernik	Major Shareholder	Sell	8,027	$39.11	$313,935.97
8/11/2014	Marcin Czernik	Major Shareholder	Sell	36,979	$37.30	$1,379,316.70
7/30/2014	Marcin Czernik	Major Shareholder	Sell	21,570	$36.20	$780,834.00
7/29/2014	Ltd Chione	Major Shareholder	Sell	30,000	$35.20	$1,056,000.00
7/23/2014	Ltd Plio	Insider	Sell	500,000	$35.54	$17,770,000.00
7/2/2014	Michael Kauffman	CEO	Sell	200,000	$42.50	$8,500,000.00
6/18/2014	Sharon Shacham	Insider	Sell	20,000	$41.76	$835,200.00
6/17/2014	Michael Kauffman	CEO	Sell	20,000	$41.76	$835,200.00
5/23/2014	Deepika Pakianathan	Director	Buy	114,419	$26.18	$2,995,489.42
5/13/2014	Paul Brannelly	SVP	Buy	1,000	$28.06	$28,060.00
11/12/2013	Deepika Pakianathan	Director	Buy	312,500	$16.00	$5,000,000.00

(Data available from 1/1/2013 forward)

Latest Headlines for Karyopharm Therapeutics (NASDAQ:KPTI)

Date	Headline
	Karyopharm Therapeutics Inc (KPTI) Given “Outperform” Rating at Wedbush - DailyQuint (NASDAQ:KPTI) dailyquint.com - September 22 at 5:39 PM
	Karyopharm Therapeutics Incorporated (NASDAQ:KPTI) Short Interest Increased By 3.25% - Post News (NASDAQ:KPTI) www.kentuckypostnews.com - September 22 at 9:03 AM
	Shares in Focus: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Earnings & Targets Update - Frisco Fastball (NASDAQ:KPTI) friscofastball.com - September 21 at 4:06 PM
	Could Karyopharm Therapeutics Inc Rise Even More? The Stock ... - Chester News (NASDAQ:KPTI) www.chesterindependent.com - September 15 at 3:46 PM
	ETF’s with exposure to Karyopharm Therapeutics, Inc. : September 14, 2016 (NASDAQ:KPTI) www.capitalcube.com - September 14 at 5:55 PM
	Earnings According to Analysts for Karyopharm Therapeutics Inc. (NASDAQ:KPTI)? - Frisco Fastball (NASDAQ:KPTI) friscofastball.com - September 14 at 10:04 AM
	Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development (NASDAQ:KPTI) www.publicnow.com - September 12 at 10:34 AM
	Placing Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares Under the Microscope - Post News (NASDAQ:KPTI) www.kentuckypostnews.com - September 8 at 5:44 PM
	Healthcare Top Losers- Tonix Pharmaceuticals (NASDAQ:TNXP), Karyopharm Therapeutics (NASDAQ:KPTI) - Seneca Globe (NASDAQ:KPTI) www.senecaglobe.com - September 8 at 5:44 PM
	Why Karyopharm Therapeutics Stock Is Falling Today (NASDAQ:KPTI) www.fool.com - September 6 at 5:51 PM
	D-Day For KPTI Today (NASDAQ:KPTI) www.rttnews.com - September 6 at 10:38 AM
	Karyopharm Therapeutics (KPTI) Announces Top-Line Selinexor Phase 2b Data in Multiple Myeloma (NASDAQ:KPTI) www.streetinsider.com - September 6 at 10:38 AM
	KARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:KPTI) biz.yahoo.com - September 6 at 10:38 AM
	Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug (NASDAQ:KPTI) www.thestreet.com - September 6 at 10:38 AM
	Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma (NASDAQ:KPTI) www.publicnow.com - September 6 at 10:38 AM
	Stock Dipping Down in Today's Session: Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) - Post News (NASDAQ:KPTI) www.kentuckypostnews.com - September 2 at 5:51 PM
	Expert Analysts Sentiments for: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) , Richmont Mines, Inc. (NYSEMKT:RIC) - Wall Street Times (press release) (NASDAQ:KPTI) www.wallstreetnews24.com - September 2 at 10:41 AM
	What Do Analysts Think Of Karyopharm Therapeutics Inc. (NASDAQ:KPTI)? (NASDAQ:KPTI) 10thousandcouples.com - September 1 at 8:55 AM
	Looking Ahead To The Karyopharm Therapeutics Inc (KPTI) MM Data (NASDAQ:KPTI) www.insidermonkey.com - September 1 at 8:55 AM
	Karyopharm Therapeutics Inc (NASDAQ:KPTI): Institutional Investor Sentiment Up to 1.54 (NASDAQ:KPTI) www.crcconnection.com - September 1 at 8:55 AM
	Karyopharm Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : KPTI-US : August 31, 2016 (NASDAQ:KPTI) www.capitalcube.com - August 31 at 10:41 AM
	Why Karyopharm Therapeutics Inc Shares Are Soaring 31% Today (NASDAQ:KPTI) www.fool.com - August 30 at 5:54 PM
	Markets Very Sluggish as August Nears an End (NASDAQ:KPTI) realmoney.thestreet.com - August 30 at 5:54 PM
	Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Expected To Post EPS Of $-0.7 - RealistInvestor.com (NASDAQ:KPTI) www.realistinvestor.com - August 30 at 9:08 AM
	Newly released market study: Karyopharm Therapeutics, Inc. (KPTI) - Financial and Strategic SWOT Analysis Review (NASDAQ:KPTI) www.live-pr.com - August 23 at 10:17 AM
	Noteworthy Monday Option Activity: KPTI, SHLD, MXWL (NASDAQ:KPTI) www.stockoptionschannel.com - August 22 at 5:55 PM
	What is Wall Street Saying About Karyopharm Therapeutics Inc. (NASDAQ:KPTI)? - Post News (NASDAQ:KPTI) www.kentuckypostnews.com - August 19 at 5:51 PM
	Will Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Hit $18 Price Target? - Investor Newswire (NASDAQ:KPTI) www.investornewswire.com - August 19 at 5:51 PM
	Pre-Open Stock Movers 8/18: (SEMI) (CIE) (RPTP) Higher; (EARS) (CERU) (PTLA) Lower (NASDAQ:KPTI) www.streetinsider.com - August 19 at 8:53 AM
	Coverage initiated on Karyopharm Therapeutics by H.C. Wainwright (NASDAQ:KPTI) finance.yahoo.com - August 18 at 5:54 PM
	Analysts See Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Reporting EPS Of $-0.7 - RealistInvestor.com (NASDAQ:KPTI) www.realistinvestor.com - August 16 at 9:08 AM
	KARYOPHARM THERAPEUTICS INC. Financials (NASDAQ:KPTI) finance.yahoo.com - August 13 at 5:41 PM
	ETF’s with exposure to Karyopharm Therapeutics, Inc. : August 8, 2016 (NASDAQ:KPTI) www.capitalcube.com - August 8 at 6:04 PM
	Edited Transcript of KPTI earnings conference call or presentation 4-Aug-16 12:30pm GMT (NASDAQ:KPTI) finance.yahoo.com - August 5 at 6:01 PM
	Karyopharm Therapeutics, Inc. :KPTI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 (NASDAQ:KPTI) www.capitalcube.com - August 5 at 6:01 PM
	Karyopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress (NASDAQ:KPTI) globenewswire.com - August 4 at 8:57 AM
	Karyopharm Therapeutics Inc.: Karyopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress (NASDAQ:KPTI) www.twst.com - August 4 at 8:57 AM
	Karyopharm Therapeutics posts 2Q loss (NASDAQ:KPTI) sg.finance.yahoo.com - August 4 at 8:57 AM
	Karyopharm to Present at Upcoming Investor Conferences (NASDAQ:KPTI) www.publicnow.com - August 3 at 9:05 AM
	Can Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Keep Up with Analyst Expectations? - Investor Newswire (NASDAQ:KPTI) www.investornewswire.com - July 31 at 5:32 PM
	Can Shares Of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Hit $20? - Investor Newswire (NASDAQ:KPTI) www.investornewswire.com - July 29 at 6:01 PM
	Karyopharm to Report Second Quarter 2016 Financial Results on August 4, 2016 (NASDAQ:KPTI) www.publicnow.com - July 28 at 8:08 AM
	Karyopharm to Present Updated Phase 2 Clinical Data from SIGN Study at European Society of Medical Oncology 2016 Annual Meeting (NASDAQ:KPTI) www.publicnow.com - July 27 at 4:28 PM
	Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published in Journal of Clinical Oncology (NASDAQ:KPTI) www.publicnow.com - July 27 at 7:38 AM
	7:34 am Karyopharm Therapeutics announces publication of data from its Phase 1b clinical trial evaluating KPT-330 in patients with advanced refractory bone or soft tissue sarcoma in the Journal of Clinical Oncology (NASDAQ:KPTI) finance.yahoo.com - July 27 at 7:34 AM
	Will Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surprise Analysts? - Investor Newswire (NASDAQ:KPTI) www.investornewswire.com - July 26 at 6:06 PM
	Is $20 Price Target Attainable For Karyopharm Therapeutics Inc. (NASDAQ:KPTI)? - Investor Newswire (NASDAQ:KPTI) www.investornewswire.com - July 24 at 10:10 AM
	Karyopharm Therapeutics Inc. (KPTI) Drops 6.82% on July 19 - Equities.com (NASDAQ:KPTI) www.equities.com - July 21 at 12:01 PM
	What Next for Karyopharm Therapeutics Inc Stock After Today's Huge Decline? - Consumer Eagle (NASDAQ:KPTI) www.consumereagle.com - July 20 at 8:51 AM
	Karyopharm Therapeutics Inc. (NASDAQ:KPTI): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:KPTI) www.engelwooddaily.com - July 20 at 8:51 AM